Impact of COVID‐19 infection on cognition and its association with neurological symptoms
Brain and Behavior · 2023-04 · 13 (4)
DOI: 10.1002/brb3.2902 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, online erschienen am 21.02.2023. Verfasst von Marta Almeria und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medicine Department, Autonomous University of Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: COVID-19, Cognition Disorders. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To characterize the cognitive profile following COVID‐19 infection and its possible association to clinical symptoms, emotional disturbance, biomarkers, and disease severity.
Methods
This was a single‐center cross‐sectional cohort study. Subjects between 20‐ and 60‐year old with confirmed COVID‐19 infection were included. Evaluation was performed between April 2020 and July 2021. Patients with previous cognitive impairment and other neurological or severe psychiatric disorders were excluded. Demographic and laboratory data were extracted from the medical records.
Results
Altogether 200 patients were included, 85 subjects were female (42.3%), and mean age was 49.12 years (SD: 7.84). Patients were classified into four groups: nonhospitalized (NH, n = 21), hospitalized without intensive care unit (ICU) nor oxygen therapy (HOSP, n = 42), hospitalized without ICU but with oxygen therapy (OXY, n = 107), and ICU (ICU, n = 31) patients. NH group was younger ( p = .026). No significant differences were found in any test performed attending severity of illness ( p > .05). A total of 55 patients reported subjective cognitive complaints (SCC). Subjects with neurological symptoms (NS) performed worse in trail making test B ( p = .013), digits backwards ( p = .006), letter&numbers ( p = .002), symbol digit modalities test ( p = .016), and Stroop color ( p = .010) tests.
Conclusions
OXY patients and females referred more SCC associated with symptoms of anxiety and depression. Objective cognitive performance was unrelated to SCC. No cognitive impairment was found regarding the severity of COVID‐19 infection. Results suggest that NS such as headache, anosmia, and dysgeusia during infection were a risk factor for later cognitive deficits. Tests assessing attention, processing speed, and executive function were the most sensitive in detecting cognitive changes in these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medicine Department, Autonomous University of Barcelona, Barcelona, Spain.
- Department of Neurology, Hospital Universitari MútuaTerrassa, Terrassa, Barcelona, Spain.
- Cognitive Impairment and Dementia Unit, Hospital Sagrat Cor, Hermanas Hospitalarias, Martorell, Barcelona, Spain.
- Department of Pneumology, Hospital Universitari MútuaTerrassa, Terrassa, Barcelona, Spain.
- Clinical and Health Department, Psychology Faculty, Autonomous University of Barcelona, Barcelona, Spain.
- MRI Research Unit, Hospital del Mar, Barcelona, Spain.
ORCID-Profile: Marta Almeria
Zitieren
APA
Almeria, M., Cejudo, J. C., Sanz-Santos, J., Deus, J., & Krupinski, J. (2023). Impact of COVID‐19 infection on cognition and its association with neurological symptoms. Brain and Behavior, 13(4). https://doi.org/10.1002/brb3.2902
Vancouver
Almeria M, Cejudo JC, Sanz-Santos J, Deus J, Krupinski J. Impact of COVID‐19 infection on cognition and its association with neurological symptoms. Brain and Behavior. 2023;13(4). doi:10.1002/brb3.2902
BibTeX
@article{Almeria2023,
author = {Almeria, Marta and Cejudo, Juan Carlos and Sanz-Santos, Jose and Deus, Joan and Krupinski, Jerzy},
title = {Impact of COVID‐19 infection on cognition and its association with neurological symptoms},
journal = {Brain and Behavior},
year = {2023},
volume = {13},
number = {4},
doi = {10.1002/brb3.2902}
}
EUVIMED